Last reviewed · How we verify
P3-Fast
At a glance
| Generic name | P3-Fast |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes (NA)
- Study of BIIB091 Formulations in Healthy Participants (PHASE1)
- Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects (PHASE1)
- A Food Effect Study of FMTN on Healthy Chinese Adult Subjects (PHASE1)
- Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation (PHASE1)
- Study of Danirixin in Japanese Healthy Elderly Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P3-Fast CI brief — competitive landscape report
- P3-Fast updates RSS · CI watch RSS
- Pfizer portfolio CI